From: Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Inhibitor | Biomarker | Cancer type | CRC patients enrollment | Phase | NCT number | Status |
---|---|---|---|---|---|---|
KRASG12C combinations | ||||||
AMG 510 and panitumumab and FOLFIRI regimen | KRASG12C mutation | Advanced solid tumors | Enrolled | Ib/II | NCT04185883 | Recruiting |
AMG 510 and trametinib and panitumumab | KRASG12C mutation | Advanced solid tumors | Enrolled | Ib/II | NCT04185883 | Recruiting |
AMG 510 and MVASI® (bevacizumab-awwb) and FOLFIRI or FOLFOX regimen | KRASG12C mutation | Advanced solid tumors | Enrolled | Ib/II | NCT04185883 | Recruiting |
MRTX849 and TN0155 | KRASG12C mutation | Advanced solid tumors | Enrolled | II | NCT04330664 | Recruiting |
MRTX849 and cetuximab | KRASG12C mutation | Advanced or metastatic CRC | Enrolled | III | NCT04793958 | Recruiting |
MRTX849 and mFOLFOX6 regimen | KRASG12C mutation | Advanced or metastatic CRC | Enrolled | III | NCT04793958 | Recruiting |
MRTX849 and FOLFIRI regimen | KRASG12C mutation | Advanced or metastatic CRC | Enrolled | III | NCT04793958 | Recruiting |
SOS inhibitors combinations | ||||||
BI 1701963 and trametinib | KRAS mutations | Advanced solid tumors | Not mentioned | I | NCT04111458 | Recruiting |
SHP2 inhibitors combinations | ||||||
RMC-4630 and LY3214996 | KRAS mutations | Advanced or metastatic solid tumors | Enrolled | I | NCT04916236 | Not yet recruiting |
TNO155 and JDQ443 | KRASG12C mutation | Advanced solid tumors | Enrolled | Ib/II | NCT04699188 | Recruiting |
RAF-MEK-ERK inhibitors combinations | ||||||
HM95573 and cobimetinib | RAS or RAF mutations | Advanced or metastatic solid tumors | Enrolled | I | NCT03284502 | Recruiting |
GDC-0994 and cobimetinib | None | Advanced or metastatic solid tumors | Enrolled | Ib | NCT02457793 | Completed |
MK-8353 and pembrolizumab | None | Advanced solid tumors | Enrolled | Ib | NCT02972034 | Active, not recruiting |
Cancer vaccines combinations | ||||||
TG02 and pembrolizumab | KRAS exon 2, codon 12 or 13 mutation | Rectal cancer | Enrolled | I | NCT02933944 | Terminated |
mRNA-5671 and pembrolizumab | KRASG12D, KRASG12V, KRASG12C, KRASG13D mutation | NSCLC, non-MSI-H CRC, PDAC | Enrolled | I | NCT03948763 | Recruiting |